La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Daiichi Sankyo Company Crescita futura

Future criteri di controllo 4/6

Daiichi Sankyo Company prevede che gli utili e i ricavi cresceranno rispettivamente di 20.3% e 13.2% all'anno. Si prevede che l'EPS crescerà di 20.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 19.6% in 3 anni.

Informazioni chiave

20.3%

Tasso di crescita degli utili

20.6%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	13.9%
Tasso di crescita dei ricavi	13.2%
Rendimento futuro del capitale proprio	19.6%
Copertura analitica	Good
Ultimo aggiornamento	19 Aug 2024

Aggiornamenti recenti sulla crescita futura

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 03

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27

Recent updates

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 03

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

May 02

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Mar 11

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

Feb 26

Previsioni di crescita degli utili e dei ricavi

TSE:4568 - Stime future degli analisti e dati finanziari passati (JPY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	2,508,822	379,089	299,520	405,452	15
3/31/2026	2,115,432	265,923	226,436	325,205	16
3/31/2025	1,818,822	210,104	77,842	306,060	16
6/30/2024	1,687,028	229,101	407,158	535,454	N/A
3/31/2024	1,601,688	200,731	476,467	599,258	N/A
12/31/2023	1,503,471	186,052	509,483	601,669	N/A
9/30/2023	1,397,025	147,885	-79,581	4,025	N/A
6/30/2023	1,348,996	147,350	15,149	89,040	N/A
3/31/2023	1,278,478	109,188	47,148	114,514	N/A
12/31/2022	1,182,201	59,354	52,831	120,225	N/A
9/30/2022	1,122,724	62,816	85,820	153,864	N/A
6/30/2022	1,061,140	50,603	74,484	148,554	N/A
3/31/2022	1,044,892	66,972	62,544	139,226	N/A
12/31/2021	1,034,692	94,470	91,294	161,092	N/A
9/30/2021	1,012,313	86,756	52,721	111,874	N/A
6/30/2021	989,638	79,321	58,547	106,238	N/A
3/31/2021	962,516	75,958	128,114	192,207	N/A
12/31/2020	963,552	70,599	123,806	188,054	N/A
9/30/2020	982,388	116,315	132,076	206,119	N/A
6/30/2020	969,501	117,584	96,878	174,904	N/A
3/31/2020	981,793	129,074	144,036	196,601	N/A
12/31/2019	983,669	148,891	137,641	212,138	N/A
9/30/2019	962,440	113,821	120,648	187,666	N/A
6/30/2019	953,219	112,805	113,638	181,424	N/A
3/31/2019	929,717	93,409	25,420	92,033	N/A
12/31/2018	922,228	66,479	38,321	85,284	N/A
9/30/2018	937,648	70,018	49,447	97,072	N/A
6/30/2018	946,829	55,081	56,120	96,957	N/A
3/31/2018	960,195	60,282	N/A	108,439	N/A
12/31/2017	961,766	37,887	N/A	99,826	N/A
9/30/2017	966,509	38,758	N/A	83,608	N/A
6/30/2017	953,255	52,017	N/A	102,946	N/A
3/31/2017	955,124	53,466	N/A	136,234	N/A
12/31/2016	962,296	59,736	N/A	161,540	N/A
9/30/2016	965,681	60,572	N/A	184,039	N/A
6/30/2016	989,001	77,951	N/A	181,513	N/A
3/31/2016	986,446	82,282	N/A	174,281	N/A
12/31/2015	839,759	55,256	N/A	139,346	N/A
9/30/2015	872,744	67,132	N/A	146,907	N/A
6/30/2015	903,340	61,708	N/A	151,239	N/A
3/31/2015	919,372	46,762	N/A	142,776	N/A
12/31/2014	1,149,342	88,276	N/A	N/A	N/A
9/30/2014	1,127,233	80,437	N/A	119,883	N/A
6/30/2014	1,120,177	69,910	N/A	N/A	N/A
3/31/2014	1,118,241	60,943	N/A	37,304	N/A
12/31/2013	1,059,287	90,021	N/A	N/A	N/A
9/30/2013	1,030,096	73,097	N/A	46,961	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 4568 ( 20.3% all'anno) è superiore al tasso di risparmio ( 0.3% ).

Guadagni vs Mercato: Si prevede che gli utili di 4568 ( 20.3% all'anno) cresceranno più rapidamente del mercato JP ( 8.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 4568 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 4568 ( 13.2% all'anno) crescerà più rapidamente del mercato JP ( 4.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 4568 ( 13.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 4568 sarà basso tra 3 anni ( 19.6 %).

Daiichi Sankyo Company Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Consensus EPS estimates increase by 10%

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Recent updates

European Medicines Agency Validates Type II Variation Application for Daiichi Sankyo Company, Limited's ENHERTU

Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥30.00

Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥30.00

Final dividend of JP¥30.00 announced

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited to Report Q1, 2025 Results on Jul 31, 2024

Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial

Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial

Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

Investor sentiment improves as stock rises 15%

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Now 27% overvalued after recent price rise

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024

Consensus EPS estimates increase by 10%

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024

Daiichi Sankyo and AstraZeneca Announces Two Phase 3 Trials of Datopotamab

Daiichi Sankyo Company, Limited to Report Q3, 2024 Results on Jan 31, 2024

Daiichi Sankyo Company, Limited Appeals Amended Texas Court Judgement in Patent Dispute with Seagen Inc

IHH Healthcare Berhad Announces Update on Claim Before the Tokyo District Court in Japan by NTK Against Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited's VANFLYTA (quizartinib) Approves in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrazeneca and Daiichi Sankyo Announces Positive Results from the Pivotal Tropion-Breast01 Phase Iii Trial

Daiichi Sankyo and Astrazeneca’S Enhertu Demonstrated Clinically Meaningful Survival Across Multiple Her2 Expressing Advanced Solid Tumors in Destiny-Pantumor02 Phase 2 Trial

Daiichi Sankyo and Astrazeneca Announce Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Daiichi Sankyo and AstraZeneca Announce Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Upcoming dividend of JP¥17.00 per share at 0.9% yield

European Union Recommends ENHERTU for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited and AstraZeneca PLC Announce Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita